Transforming big pharma: assessing the strategic alternatives
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Farnham, Surrey
Gower Publishing Limited
[2013]
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | Includes bibliographical references and index pt. I. How pharma differs and why this is important -- pt. II. Assessing management concepts for the pharmaceutical industry -- pt. III. Big pharma's strategic options -- pt. IV. Where will new products come from? -- pt. V. Prospects for new products -- pt. VI. Getting a true fix on prospects -- pt. VII. Conclusions and summary |
| Beschreibung: | 1 Online-Ressource (pages cm) |
| ISBN: | 9781409448280 1409448282 9781409448273 1409448274 9781472403643 1299925111 9781299925113 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042740047 | ||
| 003 | DE-604 | ||
| 005 | 20160111 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 150806s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9781409448280 |9 978-1-4094-4828-0 | ||
| 020 | |a 1409448282 |9 1-4094-4828-2 | ||
| 020 | |a 9781409448273 |9 978-1-4094-4827-3 | ||
| 020 | |a 1409448274 |9 1-4094-4827-4 | ||
| 020 | |a 9781472403643 |9 978-1-4724-0364-3 | ||
| 020 | |a 1299925111 |9 1-299-92511-1 | ||
| 020 | |a 9781299925113 |9 978-1-299-92511-3 | ||
| 035 | |a (OCoLC)855022848 | ||
| 035 | |a (DE-599)BVBBV042740047 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 338.4/76151 |2 23 | |
| 100 | 1 | |a Ansell, John |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Transforming big pharma |b assessing the strategic alternatives |c by John Ansell |
| 264 | 1 | |a Farnham, Surrey |b Gower Publishing Limited |c [2013] | |
| 300 | |a 1 Online-Ressource (pages cm) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a pt. I. How pharma differs and why this is important -- pt. II. Assessing management concepts for the pharmaceutical industry -- pt. III. Big pharma's strategic options -- pt. IV. Where will new products come from? -- pt. V. Prospects for new products -- pt. VI. Getting a true fix on prospects -- pt. VII. Conclusions and summary | ||
| 650 | 7 | |a BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical industry / Management |2 fast | |
| 650 | 7 | |a Strategic planning |2 fast | |
| 650 | 4 | |a Industrie | |
| 650 | 4 | |a Wirtschaft | |
| 650 | 4 | |a Pharmaceutical industry |x Management | |
| 650 | 4 | |a Strategic planning | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=620348 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBU |a ZDB-4-NLEBK | ||
| 940 | 1 | |q FLA_PDA_EBU | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028170919 | ||
Datensatz im Suchindex
| _version_ | 1804174954537680896 |
|---|---|
| any_adam_object | |
| author | Ansell, John |
| author_facet | Ansell, John |
| author_role | aut |
| author_sort | Ansell, John |
| author_variant | j a ja |
| building | Verbundindex |
| bvnumber | BV042740047 |
| collection | ZDB-4-EBU ZDB-4-NLEBK |
| ctrlnum | (OCoLC)855022848 (DE-599)BVBBV042740047 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01988nmm a2200469zc 4500</leader><controlfield tag="001">BV042740047</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160111 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">150806s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781409448280</subfield><subfield code="9">978-1-4094-4828-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1409448282</subfield><subfield code="9">1-4094-4828-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781409448273</subfield><subfield code="9">978-1-4094-4827-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1409448274</subfield><subfield code="9">1-4094-4827-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781472403643</subfield><subfield code="9">978-1-4724-0364-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1299925111</subfield><subfield code="9">1-299-92511-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781299925113</subfield><subfield code="9">978-1-299-92511-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)855022848</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042740047</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ansell, John</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transforming big pharma</subfield><subfield code="b">assessing the strategic alternatives</subfield><subfield code="c">by John Ansell</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Farnham, Surrey</subfield><subfield code="b">Gower Publishing Limited</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (pages cm)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">pt. I. How pharma differs and why this is important -- pt. II. Assessing management concepts for the pharmaceutical industry -- pt. III. Big pharma's strategic options -- pt. IV. Where will new products come from? -- pt. V. Prospects for new products -- pt. VI. Getting a true fix on prospects -- pt. VII. Conclusions and summary</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry / Management</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Strategic planning</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wirtschaft</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Strategic planning</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=620348</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBU</subfield><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">FLA_PDA_EBU</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028170919</subfield></datafield></record></collection> |
| id | DE-604.BV042740047 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:08:36Z |
| institution | BVB |
| isbn | 9781409448280 1409448282 9781409448273 1409448274 9781472403643 1299925111 9781299925113 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028170919 |
| oclc_num | 855022848 |
| open_access_boolean | |
| physical | 1 Online-Ressource (pages cm) |
| psigel | ZDB-4-EBU ZDB-4-NLEBK FLA_PDA_EBU |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Gower Publishing Limited |
| record_format | marc |
| spelling | Ansell, John Verfasser aut Transforming big pharma assessing the strategic alternatives by John Ansell Farnham, Surrey Gower Publishing Limited [2013] 1 Online-Ressource (pages cm) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index pt. I. How pharma differs and why this is important -- pt. II. Assessing management concepts for the pharmaceutical industry -- pt. III. Big pharma's strategic options -- pt. IV. Where will new products come from? -- pt. V. Prospects for new products -- pt. VI. Getting a true fix on prospects -- pt. VII. Conclusions and summary BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology bisacsh Pharmaceutical industry / Management fast Strategic planning fast Industrie Wirtschaft Pharmaceutical industry Management Strategic planning http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=620348 Aggregator Volltext |
| spellingShingle | Ansell, John Transforming big pharma assessing the strategic alternatives BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology bisacsh Pharmaceutical industry / Management fast Strategic planning fast Industrie Wirtschaft Pharmaceutical industry Management Strategic planning |
| title | Transforming big pharma assessing the strategic alternatives |
| title_auth | Transforming big pharma assessing the strategic alternatives |
| title_exact_search | Transforming big pharma assessing the strategic alternatives |
| title_full | Transforming big pharma assessing the strategic alternatives by John Ansell |
| title_fullStr | Transforming big pharma assessing the strategic alternatives by John Ansell |
| title_full_unstemmed | Transforming big pharma assessing the strategic alternatives by John Ansell |
| title_short | Transforming big pharma |
| title_sort | transforming big pharma assessing the strategic alternatives |
| title_sub | assessing the strategic alternatives |
| topic | BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology bisacsh Pharmaceutical industry / Management fast Strategic planning fast Industrie Wirtschaft Pharmaceutical industry Management Strategic planning |
| topic_facet | BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology Pharmaceutical industry / Management Strategic planning Industrie Wirtschaft Pharmaceutical industry Management |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=620348 |
| work_keys_str_mv | AT anselljohn transformingbigpharmaassessingthestrategicalternatives |